Historical Valuation
Cullinan Therapeutics Inc (CGEM) is now in the Overvalued zone, suggesting that its current forward PS ratio of 95.66 is considered Overvalued compared with the five-year average of -6.59. The fair price of Cullinan Therapeutics Inc (CGEM) is between 4.28 to 9.19 according to relative valuation methord. Compared to the current price of 10.90 USD , Cullinan Therapeutics Inc is Overvalued By 18.58%.
Relative Value
Fair Zone
4.28-9.19
Current Price：10.90
18.58%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Cullinan Therapeutics Inc (CGEM) has a current Price-to-Book (P/B) ratio of 1.32. Compared to its 3-year average P/B ratio of 1.15 , the current P/B ratio is approximately 14.70% higher. Relative to its 5-year average P/B ratio of 1.32, the current P/B ratio is about 0.26% higher. Cullinan Therapeutics Inc (CGEM) has a Forward Free Cash Flow (FCF) yield of approximately -29.16%. Compared to its 3-year average FCF yield of -27.81%, the current FCF yield is approximately 4.83% lower. Relative to its 5-year average FCF yield of -19.95% , the current FCF yield is about 46.17% lower.
P/B
Median3y
1.15
Median5y
1.32
FCF Yield
Median3y
-27.81
Median5y
-19.95
Competitors Valuation Multiple
AI Analysis for CGEM
The average P/S ratio for CGEM competitors is 37.57, providing a benchmark for relative valuation. Cullinan Therapeutics Inc Corp (CGEM.O) exhibits a P/S ratio of 95.66, which is 154.59% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CGEM
1Y
3Y
5Y
Market capitalization of CGEM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CGEM in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CGEM currently overvalued or undervalued?
Cullinan Therapeutics Inc (CGEM) is now in the Overvalued zone, suggesting that its current forward PS ratio of 95.66 is considered Overvalued compared with the five-year average of -6.59. The fair price of Cullinan Therapeutics Inc (CGEM) is between 4.28 to 9.19 according to relative valuation methord. Compared to the current price of 10.90 USD , Cullinan Therapeutics Inc is Overvalued By 18.58% .
What is Cullinan Therapeutics Inc (CGEM) fair value?
CGEM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cullinan Therapeutics Inc (CGEM) is between 4.28 to 9.19 according to relative valuation methord.
How does CGEM's valuation metrics compare to the industry average?
The average P/S ratio for CGEM's competitors is 37.57, providing a benchmark for relative valuation. Cullinan Therapeutics Inc Corp (CGEM) exhibits a P/S ratio of 95.66, which is 154.59% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Cullinan Therapeutics Inc (CGEM) as of Jan 10 2026?
As of Jan 10 2026, Cullinan Therapeutics Inc (CGEM) has a P/B ratio of 1.32. This indicates that the market values CGEM at 1.32 times its book value.
What is the current FCF Yield for Cullinan Therapeutics Inc (CGEM) as of Jan 10 2026?
As of Jan 10 2026, Cullinan Therapeutics Inc (CGEM) has a FCF Yield of -29.16%. This means that for every dollar of Cullinan Therapeutics Inc’s market capitalization, the company generates -29.16 cents in free cash flow.
What is the current Forward P/E ratio for Cullinan Therapeutics Inc (CGEM) as of Jan 10 2026?
As of Jan 10 2026, Cullinan Therapeutics Inc (CGEM) has a Forward P/E ratio of -3.14. This means the market is willing to pay $-3.14 for every dollar of Cullinan Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Cullinan Therapeutics Inc (CGEM) as of Jan 10 2026?
As of Jan 10 2026, Cullinan Therapeutics Inc (CGEM) has a Forward P/S ratio of 95.66. This means the market is valuing CGEM at $95.66 for every dollar of expected revenue over the next 12 months.